Genzyme Corp. and Arecor Ltd. have entered an extensive collaboration agreement to develop advanced formulations for protein therapeutics. The two companies will work together to develop stable, high strength formulations of labile biomolecules. Dr. Robert Mattaliano, group vice president of Therapeutic Protein R&D commented, “The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles. Genz...